Evidence map›Paper›PMID 35563278›Full record

ArticleInternational journal of molecular sciences2022

Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA.

Nico Dreymann, Julia Wuensche, Wiebke Sabrowski, Anja Moeller, Denise Czepluch, Dana Vu Van, Susanne Fuessel, Marcus M Menger

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. HIV-HPV interactions via extracellular vesicles among tobacco smokers and nonsmokers.Experimental biology and medicine (Maywood, N.J.) · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Nico DreymannFraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), D-14476 Potsdam, Germany.ORCID 0000-0002-0707-7946
Julia WuenscheRiNA GmbH, D-12489 Berlin, Germany.
Wiebke SabrowskiFraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), D-14476 Potsdam, Germany.ORCID 0000-0001-9362-2586
Anja MoellerFraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), D-14476 Potsdam, Germany.
Denise CzepluchFraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), D-14476 Potsdam, Germany.
Dana Vu VanDepartment of Urology, Technische Universität Dresden, D-01307 Dresden, Germany.
Susanne FuesselDepartment of Urology, Technische Universität Dresden, D-01307 Dresden, Germany.
Marcus M MengerFraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), D-14476 Potsdam, Germany.ORCID 0000-0002-6856-6663
Fraunhofer Institute for Cell Therapy and Immunology · DETechnische Universität Dresden · DERiNA (Germany) · DEUniversity of Potsdam · DE

Funding

Federal Ministry of Education and Research 16SV6070Federal Ministry of Education and Research 16SV6072Ministerium für Wissenschaft, Forschung und Kultur 85017631
6 · The paper itself

Abstract

Urokinase-type plasminogen activator is widely discussed as a marker for cancer prognosis and diagnosis and as a target for cancer therapies. Together with its receptor, uPA plays an important role in tumorigenesis, tumor progression and metastasis. In the present study, systematic evolution of ligands by exponential enrichment (SELEX) was used to select single-stranded DNA aptamers targeting different forms of human uPA. Selected aptamers allowed the distinction between HMW-uPA and LMW-uPA, and therefore, presumably, have different binding regions. Here, uPAapt-02-FR showed highly affine binding with a K

Indexed as

Aptamers, NucleotideNeoplasmsAnimalsHumansLigandsMiceProtein BindingUrokinase-Type Plasminogen ActivatorAptamers, NucleotideLigandsUrokinase-Type Plasminogen Activatorbiomarkercancercancer therapyDNA aptamermicroscale thermophoresis (MST)SELEXsurface plasmon resonance spectroscopy (SPR)uPAuPARurokinase

Identifiers

PMID35563278
PMCPMC9100121
OpenAlexW4225012088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.